LISATA THERAPEUTICS, INC. — Director's Dealing 2021

Jan 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2021-01-13

Reporting Person: Mazzo David J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-13	Common Stock	A	39000	—	Acquired	333653	Direct
2021-01-13	Common Stock	F	21787	$1.55	Disposed	311866	Direct
2021-01-13	Common Stock	F	6425	$1.55	Disposed	305441	Direct
2021-01-14	Common Stock	F	5936	$1.56	Disposed	299505	Direct

Footnotes

F1: Reflects 39,000 in performance rights, the criteria for which was satisfied on January 13, 2021 and which vested on that same date.

F2: Shares withheld as payment of a tax liability on vesting of restricted stock.

F3: Includes 147,250 unvested restricted stock.

F4: Includes 135,750 unvested restricted stock.

F5: Includes 124,000 unvested restricted stock.